PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; anzu-cel received Orphan Drug Designation from the FDA for the treatment of ...

Company is well positioned following positive FDA Type B meeting outcome, fully enrolled Phase 2 trial for its lead clinical program, and recent $5 million public offering, as commercial operation ...

A 5-day amoxicillin challenge was feasible for evaluating delayed penicillin allergy, with more than 80% of participants completing the protocol; immune‑mediated reactions were uncommon but occurred ...

Tycoon2FA has become a leading phishing-as-a-service (PhaaS) platforms, enabling campaigns that reach over 500,000 organizations monthly, prompting Microsoft’s Digital Crimes Unit (DCU) to work with ...

A closer look at a recent study reveals that vegans have significantly lower inflammatory markers than vegetarians and meat ...

Physical exertion combined with deep concentration can severely slow down human reaction times. A recent trial reveals that ...

Tools designed to verify and monitor physical AI systems offer value, but human oversight is needed to prevent accidents and unexpected behavior.

Clinical trials and equitable care pathways are needed to build on early evidence of benefit Substance use disorders (SUDs) are common and burdensome for patients, families, and health systems,12 yet ...

TD Cowen 46th Annual Health Care Conference March 2, 2026 11:10 AM ESTCompany ParticipantsJan Mikkelsen - President, CEO, ...

An ongoing Phase III trial aims to further evaluate the drug's clinical efficacy in reducing seizures and affecting behavior and cognition.

The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular outcomes in persons with type 2 diabetes and chronic kidney disease (CKD).

The only approved gene therapy for RP today targets a single gene RPE65, which accounts for just 1% to 2% of the total RP patient population. We believe OCU400 has significantly wider commercial ...